Cacildo Magul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cacildo Magul has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Aleny Couto
National HIV and STI Control Program, Ministry of Health, Salvador Allende 1008, Maputo 1101, Mozambique
1 shared publication - Amancio Nhangave
Operational Research Unit, Gaza Provincial Health Directorate, Rua do Hospital Provincial, 33 Bairro 13, Cidade de Xai-Xai 1200, Mozambique
1 shared publication - Ana Muteerwa
Division of Global HIV & TB, U.S. Centers for Diseases Control and Prevention, Avenida Marginal 5467, Maputo 1101, Mozambique
1 shared publication - Artur Ramos
Division of Global HIV & TB, U.S. Centers for Diseases Control and Prevention, Avenida Marginal 5467, Maputo 1101, Mozambique
1 shared publication - Christina S. Polyak
PATH, Seattle, WA 98121, USA
1 shared publication - Cidia Hussein
Elizabeth Glaser Pediatric AIDS Foundation, Avenida Paulo Samuel KanKhomba, 280 Bairro da Sommerschield, Maputo 20005, Mozambique
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by Elsevier in SSRN Electronic Journal
A Resilient and Sustainable Genomic Integration through the One Health Approach: Key Outcomes from the National Workshops in Mozambique, 2025
Background: Genomics has emerged as an important tool for public health systems, particularly following the COVID-19 pandemic, which accelerated sequencing capacity globally, enabling early detection of emerging pathogens, monitoring antimicrobial resistance, and informing precision health interventions. In Mozambique, integrating genomics within a One Health approach recognises the advances in interconnectedness of human, animal, plant, and environmental health systems, strengthening coordinated integration and preparedness for emerging health threats.Methods: Between March and August 2025, four national consultative workshops were conducted in Maputo to develop, finalize and launch the PLAGIM. Stakeholders from the human, animal, environmental, and plant health sectors participated in a structured process to assess in country existing capacities, define priority pathogens and diseases, develop strategic objectives and design a monitoring and evaluation plan. SWOT analysis was used to assess the national genomics landscape, and the WHO Genomic Costing Tool was applied to estimate implementation costs and guide resource allocation.Findings: Five thematic areas were identified, namely genomics and bioinformatics workforce development; establishment of an integrated genomic surveillance network; implementation of genomics within a One Health framework; strengthening genomic data analysis, sharing, and use for decision-making; and development of quality management systems. A monitoring and evaluation framework with defined indicators and milestones was developed. A list of priority pathogens and diseases were defined under One Health approach. Costing data indicated that reagents and consumables represent the largest share of implementation expenditures (56·0% of the total cost), followed by equipment (18·0%).Interpretation: PLAGIM demonstrates how genomics can be effectively integrated and operationalised into national health systems through a One Health approach, providing a scalable framework for strengthening coordinated genomic activities and supporting evidence-based public health decision-making in Mozambique and other low- and middle-income countries.
- 18 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Resilient and Sustainable Genomic Integration through the One Health Approach: Key Outcomes from the National Workshops in Mozambique, 2025
Background: Genomics has emerged as an important tool for public health systems, particularly following the COVID-19 pandemic, which accelerated sequencing capacity globally, enabling early detection of emerging pathogens, monitoring antimicrobial resistance, and informing precision health interventions. In Mozambique, integrating genomics within a One Health approach recognises the advances in interconnectedness of human, animal, plant, and environmental health systems, strengthening coordinated integration and preparedness for emerging health threats.Methods: Between March and August 2025, four national consultative workshops were conducted in Maputo to develop, finalize and launch the PLAGIM. Stakeholders from the human, animal, environmental, and plant health sectors participated in a structured process to assess in country existing capacities, define priority pathogens and diseases, develop strategic objectives and design a monitoring and evaluation plan. SWOT analysis was used to assess the national genomics landscape, and the WHO Genomic Costing Tool was applied to estimate implementation costs and guide resource allocation.Findings: Five thematic areas were identified, namely genomics and bioinformatics workforce development; establishment of an integrated genomic surveillance network; implementation of genomics within a One Health framework; strengthening genomic data analysis, sharing, and use for decision-making; and development of quality management systems. A monitoring and evaluation framework with defined indicators and milestones was developed. A list of priority pathogens and diseases were defined under One Health approach. Costing data indicated that reagents and consumables represent the largest share of implementation expenditures (56·0% of the total cost), followed by equipment (18·0%).Interpretation: PLAGIM demonstrates how genomics can be effectively integrated and operationalised into national health systems through a One Health approach, providing a scalable framework for strengthening coordinated genomic activities and supporting evidence-based public health decision-making in Mozambique and other low- and middle-income countries.
- Open Access
HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months who transitioned to TLD and had unsuppressed viral load (VL) ≥ 1000 copies/mL six months post-transition. After three adherence counseling sessions, participants with VF underwent genotyping for drug resistance mutations (DRMs) using the Stanford HIVdb Program. Of 717 participants (median age 39.2 years, 70.7% female), 217 (30.2%) had VF, 193 (88.9%) underwent genotyping, with 183 (94.8%) successfully genotyped. Intermediate–high dolutegravir (DTG) resistance was found in 19.6% (36/183). Unsuppressed VL before DTG transition was independently associated with VF (aOR: 2.14). Resistance patterns included 33.3% (12/36; 95% CI: 14.6–46.3) to all three TLD drugs, 55.6% (20/36; 95% CI: 39.3–71.9) to DTG and 3TC, and 11% (4/36; 95% CI: 0.8–21.3) to DTG only. Major drug resistance mutations to DTG included G118R (9.3%), R263K (6.6%), and Q148H/R/K (4.4%). This study highlights the need to consider virologic status before transitioning PLHIV to TLD and suggests that adherence counseling may not prevent resistance in those with unknown or prior VF.
Open AccessHIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months who transitioned to TLD and had unsuppressed viral load (VL) ≥ 1000 copies/mL six months post-transition. After three adherence counseling sessions, participants with VF underwent genotyping for drug resistance mutations (DRMs) using the Stanford HIVdb Program. Of 717 participants (median age 39.2 years, 70.7% female), 217 (30.2%) had VF, 193 (88.9%) underwent genotyping, with 183 (94.8%) successfully genotyped. Intermediate–high dolutegravir (DTG) resistance was found in 19.6% (36/183). Unsuppressed VL before DTG transition was independently associated with VF (aOR: 2.14). Resistance patterns included 33.3% (12/36; 95% CI: 14.6–46.3) to all three TLD drugs, 55.6% (20/36; 95% CI: 39.3–71.9) to DTG and 3TC, and 11% (4/36; 95% CI: 0.8–21.3) to DTG only. Major drug resistance mutations to DTG included G118R (9.3%), R263K (6.6%), and Q148H/R/K (4.4%). This study highlights the need to consider virologic status before transitioning PLHIV to TLD and suggests that adherence counseling may not prevent resistance in those with unknown or prior VF.
- Open Access
- 14 March 2022
- Published by Springer Nature in BMC Immunology
- Vol. 23 (1) , 1-9
Helios expressing regulatory T cells are correlated with decreased IL-2 producing CD8 T cells and antibody diversity in Mozambican individuals living chronically with HIV-1
Background: Human immunodeficiency virus type 1 (HIV-1) causes impairment of T and B cell responses, which begins during the acute phase of infection and is not completely restored by antiretroviral treatment. Regulatory T cell (Tregs) can improve overall disease outcome by controlling chronic inflammation but may also suppress beneficial HIV-1 specific immune responses. We aimed to analyze the profile of Tregs and their correlation with the status of T cells activation, the expression of IL-2 and IFNγ and the profile of HIV-1 specific antibodies response in Mozambican people living chronically with HIV-1 (PLWH-C). Results: In PLWH-C, the proportion of total Tregs was positively correlated with the proportion of IL-2+CD4 T cells (r = 0.647; p = 0.032) and IL-2+IFNγ+CD8 T cells (r = 0.551; p = 0.014), while the proportions of Helios+Tregs correlated inversely with levels of IL-2+CD8 T cells (r = − 0.541; p = 0.017). Overall, PLWH-C, with (82%) or without virologic suppression (64%), were seronegative for at least HIV-1 p31, gp160 or p24, and the breadth of antibody responses was positively correlated with proportions of CD38+HLA-DR+CD8 T cells (r = 0.620; p = 0.012), viral load (r = 0.452; p = 0.040) and inversely with absolute CD4 T cells count (r = − 0.481; p = 0.027). Analysis of all individuals living HIV-1 showed that the breadth of HIV-1 antibody responses was inversely correlated with the proportion of Helios+Tregs (r = − 0.45; p = 0.02). Conclusion: Among Mozambican people living with HIV-1, seronegativity to some HIV-1 proteins is common, particularly in virologically suppressed individuals. Furthermore, lower diversity of HIV-specific antibodies is correlated to lower immune activation, lower viral replication and higher CD4 counts, in PLWH-C. Elevation in the proportion of Helios+Tregs is related to a reduction of CD8 T expressing intracellular IL-2, in PLWH-C, but may contribute to impairment of B cell function.
- 14 March 2022
- Published by Springer Nature in BMC Immunology
- Vol. 23 (1) , 1-9
Open AccessHelios expressing regulatory T cells are correlated with decreased IL-2 producing CD8 T cells and antibody diversity in Mozambican individuals living chronically with HIV-1
Background: Human immunodeficiency virus type 1 (HIV-1) causes impairment of T and B cell responses, which begins during the acute phase of infection and is not completely restored by antiretroviral treatment. Regulatory T cell (Tregs) can improve overall disease outcome by controlling chronic inflammation but may also suppress beneficial HIV-1 specific immune responses. We aimed to analyze the profile of Tregs and their correlation with the status of T cells activation, the expression of IL-2 and IFNγ and the profile of HIV-1 specific antibodies response in Mozambican people living chronically with HIV-1 (PLWH-C). Results: In PLWH-C, the proportion of total Tregs was positively correlated with the proportion of IL-2+CD4 T cells (r = 0.647; p = 0.032) and IL-2+IFNγ+CD8 T cells (r = 0.551; p = 0.014), while the proportions of Helios+Tregs correlated inversely with levels of IL-2+CD8 T cells (r = − 0.541; p = 0.017). Overall, PLWH-C, with (82%) or without virologic suppression (64%), were seronegative for at least HIV-1 p31, gp160 or p24, and the breadth of antibody responses was positively correlated with proportions of CD38+HLA-DR+CD8 T cells (r = 0.620; p = 0.012), viral load (r = 0.452; p = 0.040) and inversely with absolute CD4 T cells count (r = − 0.481; p = 0.027). Analysis of all individuals living HIV-1 showed that the breadth of HIV-1 antibody responses was inversely correlated with the proportion of Helios+Tregs (r = − 0.45; p = 0.02). Conclusion: Among Mozambican people living with HIV-1, seronegativity to some HIV-1 proteins is common, particularly in virologically suppressed individuals. Furthermore, lower diversity of HIV-specific antibodies is correlated to lower immune activation, lower viral replication and higher CD4 counts, in PLWH-C. Elevation in the proportion of Helios+Tregs is related to a reduction of CD8 T expressing intracellular IL-2, in PLWH-C, but may contribute to impairment of B cell function.